Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis

類似資料

• Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis
  著者:: Pinelopi Arvaniti, 等
  出版事項: (2020-08-01)
• Postinfantile Giant Cell Hepatitis with Features of Acute Severe Autoimmune Hepatitis Probably Triggered by Diclofenac in a Patient with Primary Myelofibrosis
  著者:: Arvaniti, Pinelopi, 等
  出版事項: (2018)
• Severe Pharyngodynia Followed by Migratory Polyarthritis and High Fever in Young Immigrants: Remember That Rheumatic Fever Is Still Relevant in 2020!
  著者:: Azariadis, Kalliopi, 等
  出版事項: (2020)
• Cell-specific epigenome-wide DNA methylation in peripheral CD4(+) lymphocytes from patients with primary biliary cholangitis
  著者:: Pinelopi Arvaniti, 等
  出版事項: (2025-12-01)
• Autoimmune hepatitis, one disease with many faces: Etiopathogenetic, clinico-laboratory and histological characteristics
  著者:: Gatselis, Nikolaos K, 等
  出版事項: (2015)